florfenicol / meloxicam
This is a summary of the European public assessment report (EPAR) for Zeleris.It explains how the Agency assessed this veterinary medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Zeleris.
For practical information about using Zeleris, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.
Zeleris : EPAR - Summary for the public (PDF/83.27 KB)
First published: 30/05/2017
Last updated: 30/05/2017
|Agency product number||
|International non-proprietary name (INN) or common name||
|Anatomical therapeutic chemical veterinary (ATCvet) codes||
CEVA Santé Animale
|Date of issue of marketing authorisation valid throughout the European Union||
10, avenue de La Ballastière
15/05/2017 Zeleris - EMEA/V/C/004099 -
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Antibacterials for systemic use
For therapeutic treatment of bovine respiratory disease (BRD) associated with pyrexia due to Mannheimia haemolytica, Pasteurella multocida and Histophilus somni susceptible to florfenicol.
Meeting highlights from the Committee for Medicinal Products for Veterinary Use (CVMP) 7-9 December 202110/12/2021
Meeting highlights from the Committee for Medicinal Products for Veterinary Use (CVMP) 13-15 April 202116/04/2021